福坦替尼治疗免疫性血小板减少症患者的真实世界疗效与安全性:意大利多中心经验(GIMEMA ITP1122研究)
这项意大利多中心回顾性观察研究纳入95例持续/慢性免疫性血小板减少症(p/c ITP)患者,评估福坦替尼真实世界结局。总缓解率73%(完全缓解32%),45%患者用药达6个月,中位治疗时长7.3个月;38例报告59起不良事件,多为1-2级,8%因不良事件停药。
要点
- 总缓解率73%,完全缓解32%,74%的患者在首月内获得缓解。
- 45%的患者福坦替尼治疗持续6个月,中位治疗时长7.3个月。
- 38例报告59起不良事件,多为1-2级,8%因不良事件停药。
核心结论
- 真实世界数据证实福坦替尼是复发/难治性ITP有效且安全的选择。
研究设计与样本
- 回顾性、多中心观察性研究,连续纳入意大利20个中心的95例持续/慢性ITP患者,59%为女性,中位年龄64岁(范围21-86)。
- 从ITP诊断到福坦替尼启动的中位时间为7.7年,既往治疗中位数为4种,54%的患者接受过一种以上血小板生成素受体激动剂(TPO-RA),23%接受过脾切除术。
主要发现
- 总缓解率为73%,完全缓解率为32%,74%的患者在首月内获得缓解。
- 45%的患者接受福坦替尼治疗达6个月,中位治疗时长为7.3个月。
- 停药的主要原因为治疗失败(43%)。
- 38例患者共报告59起不良事件,多为1-2级,8%的患者因不良事件停用福坦替尼。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The efficacy and safety of fostamatinib in adult patients with persistent/chronic immune thrombocytopenia (p/c ITP) were demonstrated in the FIT-1/FIT-2 trials. This retrospective, multicentre observational study evaluated real-world outcomes in consecutive p/c ITP patients treated with fostamatinib in Italy. The primary end-point, serving as a surrogate for both efficacy and safety, was the proportion of patients receiving fostamatinib for at least 6 months. Ninety-five patients were enrolled across 20 Italian centres, 59% female, median age 64 years (range 21-86). The median time from ITP diagnosis to fostamatinib initiation was 7.7 years; the median number of prior therapies was 4, including 54% of patients who received more than one thrombopoietin receptor agonist (TPO-RA) and 23% who underwent splenectomy. The overall response rate was 73%, with 32% complete responses. Most patients (74%) achieved a response within the first month. Concerning the primary end-point, 45% of patients received fostamatinib for 6 months; the median treatment duration was 7.3 months. The main cause of discontinuation was treatment failure (43%). Fifty-nine adverse events were reported in 38 patients, mostly grade 1-2, leading to fostamatinib discontinuation in 8% of patients. This real-world data confirm fostamatinib as an effective and safe option in relapsed/refractory ITP.
引用
- Lucchini E, Vianelli N, Consoli U, et al. Real-world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study. Br J Haematol. 2025. PMID: 40855761. doi:10.1111/bjh.70069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。